WHO Prequalification CMC — The Technical Dossier Requirements for Global Access and Procurement Programs

Your FDA ANDA approval demonstrates cGMP manufacturing and bioequivalent performance to the FDA reference listed drug. WHO Prequalification assessors will not use it as the basis for WHO PQ approval.

They assess the WHO Technical Dossier against WHO’s own guidelines, compare the product to the WHO Reference Product, which may not be the FDA RLD at all, and require twelve months of real-time Zone IVb stability data at 30°C/75% RH before approval is possible. The WHO PQ process runs about 18 months, and that clock effectively can’t start moving toward approval until the Zone IVb stability data reaches its 12-month time point.

WHO Zone IVb Stability — 30°C/75% RH as the Primary Long-Term Condition for Tropical Market Medicines and the 12-Month Real-Time Data Requirement That FDA ANDA Packages Cannot Satisfy

WHO’s Stability Testing Guidelines classify climate zones for stability purposes across five categories: Zone I at 21°C/45% RH for temperate climates, Zone II at 25°C/60% RH for Mediterranean and subtropical conditions, Zone III at 30°C/35% RH for hot, dry climates, Zone IVa at 30°C/65% RH for hot, humid conditions, and Zone IVb at 30°C/75% RH for hot, very humid conditions. Sub-Saharan Africa and South Asia, the principal procurement markets for WHO PQ-approved antiretrovirals, antimalarials, and anti-tuberculosis medicines, fall within Zone IVb, and WHO PQ requires Zone IVb data as the primary long-term condition rather than an accepted alternative to a Zone I/II dataset. The minimum expectation is real-time data at 30°C/75% RH through at least the 3, 6, 9, and 12-month time points before approval, with 24-month data required to support a shelf life of 24 months or longer, and accelerated data at 40°C/75% RH through 6 months submitted alongside it. Critically, WHO PQ does not accept ICH Q1E-style extrapolation from accelerated data alone to establish Zone IVb shelf life; the real-time long-term dataset itself has to reach the proposed shelf life support point. An applicant arriving with a typical FDA ANDA stability package at filing, six months of 40°C/75% RH accelerated data and six months of 25°C/60% RH real-time data supporting a 24-month shelf life proposal, has a dossier that’s structurally sound for FDA purposes but doesn’t contain the Zone IVb condition at all, and WHO’s response is a List of Questions requesting Zone IVb data initiation, with approval unavailable until the 12-month real-time Zone IVb dataset is actually generated and submitted.

WHO Reference Product vs. FDA RLD — Comparator Identification, Cross-Reference Dissolution Comparison, and the BE Study Consequences When They Are Not Pharmaceutically Equivalent

WHO’s bioequivalence guideline defines the WHO Reference Product, the comparator against which a multisource product must demonstrate bioequivalence, as the innovator medicine marketed in a WHO PQ member country, and for many essential medicines that comparator isn’t the same physical product as the FDA reference listed drug. Efavirenz illustrates the pattern directly: the FDA RLD is Sustiva, marketed by Bristol-Myers Squibb in the United States, while the WHO comparator commonly used for essential-medicine BE purposes is Stocrin, marketed by Merck Sharp & Dohme across much of the rest of the world including South Africa. Both products share the same active pharmaceutical ingredient, but as separately manufactured products they can carry different excipient compositions and, as a result, different dissolution characteristics, meaning a bioequivalence study conducted against Sustiva doesn’t automatically establish bioequivalence against Stocrin for WHO PQ purposes. WHO’s expectation, absent a direct BE study against the actual WHO comparator, is a dissolution cross-comparison between the FDA RLD and the WHO comparator across at least three pH media, with an f2 similarity factor of 50 or above required in each medium to establish that the two comparators are pharmaceutically equivalent and that a BE study run against one is valid evidence for the other. Where that f2 comparison falls below 50 in any medium, the FDA RLD-referenced BE study doesn’t transfer, and a new bioequivalence study conducted directly against the WHO comparator becomes necessary, a WHO List of Questions finding that surfaces specifically because the comparator identification step was skipped or assumed rather than confirmed.

WHO GMP Certificate, Inspectorate, and SRA Equivalence — The GMP Compliance Pathway for WHO PQ and What an FDA Warning Letter Does to Your WHO PQ Standing

WHO PQ’s GMP compliance verification runs through one of two recognized pathways: a current WHO GMP certificate issued directly by the WHO Inspectorate following its own site inspection, or a current GMP certificate from a WHO-recognized Stringent Regulatory Authority, which includes FDA, EMA member state authorities, TGA, Health Canada, and PMDA among others. That SRA-equivalence pathway is what lets many manufacturers avoid a separate WHO Inspectorate inspection entirely, relying instead on their existing FDA or EMA GMP standing, but it carries a specific condition: a site currently holding outstanding FDA 483 observations or a Warning Letter isn’t considered GMP-compliant under WHO’s SRA equivalence recognition, regardless of that site’s underlying FDA registration status. A manufacturing site that assumes its FDA-registered status alone satisfies WHO’s GMP requirement, without confirming that no unresolved Warning Letter or open 483 finding exists at the time of WHO PQ assessment, risks discovering the gap specifically when WHO’s Quality Assessment Team cross-checks GMP standing against current FDA compliance status rather than historical registration alone, a finding that can trigger a WHO Inspectorate site inspection where SRA recognition would otherwise have been the faster path.

The XGene WHO PQ Technical Dossier CMC Architecture — Zone IVb Stability Design, Comparator Identification, FDC Dissolution Protocol, GMP Certification Pathway, and LOQ Response Strategy

The XGene WHO PQ Technical Dossier CMC Architecture is a structured CMC strategy for WHO Prequalification submissions built around the recognition that a Technical Dossier prepared to FDA or EMA standards has to be independently re-verified against WHO’s own comparator, stability zone, and GMP recognition framework before submission.

1. Zone IVb Stability Program Design — Initiate 30°C/75% RH long-term stability testing early enough that 12-month real-time data is available before the target WHO PQ approval date, alongside the required 40°C/75% RH accelerated arm. 2. WHO Reference Product Identification — Confirm the actual WHO comparator product for the specific essential medicine and market, rather than assuming the FDA RLD serves as the comparator by default. 3. Cross-Reference Dissolution Comparison Protocol — Where a BE study exists only against the FDA RLD, run the f2 ≥50 dissolution comparison against the WHO comparator across the required pH media before assuming the existing BE study transfers. 4. FDC Dissolution Protocol Compliance — For fixed-dose combination products, confirm dissolution profiles are generated in every pH medium WHO’s guideline requires for each active ingredient, not only the standard three-medium set. 5. GMP Certification Pathway Verification — Confirm current, unresolved-finding GMP standing with the relevant Stringent Regulatory Authority before relying on SRA equivalence rather than a WHO Inspectorate inspection.

The output is the WHO PQ CMC strategy that treats Zone IVb stability, comparator identification, and GMP recognition as independent verification steps, rather than assumptions carried over from an existing FDA or EMA approval.

WHO Technical Report Series No. 992 (2015) establishes the WHO PQ Technical Dossier quality requirements this article’s analysis is built around, while WHO TRS 1010, Annex 10 (2018) establishes the Zone IVb stability classification and the 12-month real-time data requirement for tropical-market medicines. WHO TRS 992, Annex 7 (2015) establishes the WHO Reference Product comparator standard and BCS-based biowaiver criteria, and WHO TRS 929, Annex 5 (2005) establishes the fixed-dose combination dissolution comparison requirement across multiple pH media. WHO’s GMP Inspection Programme establishes the WHO Inspectorate and Stringent Regulatory Authority equivalence pathways for manufacturing site GMP compliance verification.

For your WHO PQ submission, have you confirmed that Zone IVb stability studies at 30°C/75% RH are running with 12-month real-time data scheduled to be available before your target approval date, identified the actual WHO Reference Product for your essential medicine and performed a dissolution cross-comparison against your FDA RLD in the required pH media, and verified that your manufacturing site’s GMP standing carries no outstanding Warning Letter or 483 observation that would disqualify SRA equivalence recognition?